Freda C Lewis-Hall
CIK 1437909 · Executive Vice President · last filed 2026-03-25
Freda C Lewis-Hall is an Executive Vice President who has filed 150 SEC Form 4 insider transactions across 9 companies since 2008. The most recent filing, for PYXS, was dated Mar 25, 2026. Across all open-market trades the lifetime net is −$310.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $45.3M across reported positions. 32 SEC filings were submitted jointly with PFIZER INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$45.30M
9
150
-$310.1K
Filer Profile
130 WAVERLY STREET
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PYXS | Director | 241,405 | $3.21 | $774.9K | $0 | 6 | 2026-03-25 |
| CDTTW | Director | 39,801 | $0.01 | $394 | $0 | 4 | 2025-08-26 |
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | Director | 4,017,245 | $46.99 | $188.77M | $900.0K | 9 | 2025-07-02 |
| CDT | Director | — | $0.25 | — | $0 | 1 | 2023-12-14 |
| EXACT SCIENCES CORP (EXAS) Delisted | Director | 19,688 | $104.91 | $2.07M | $0 | 5 | 2023-06-12 |
| 1Life Healthcare Inc (ONEM) Delisted | Director | 4,534 | $16.47 | $74.7K | $0 | 3 | 2022-06-06 |
| PFE | Executive Vice President | 468,690 | $27.72 | $12.99M | -$1.10M | 113 | 2019-03-01 |
| THC | Director | 15,314 | $263.69 | $4.04M | $0 | 3 | 2016-05-17 |
| VRTX | EVP, Medicines Development | 53,334 | $515.44 | $27.49M | -$106.3K | 5 | 2009-03-20 |
Recent Filings
150 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-25 | PYXS | Grant (A) | — | $0 | EDGAR |
| 2025-08-26 | CDTTW | Grant (A) | +35,000 | $0 | EDGAR |
| 2025-07-02 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Disp (D) | −24,727 | $0 | EDGAR |
| 2025-05-15 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Grant (A) | +10,060 | $0 | EDGAR |
| 2025-04-02 | PYXS | Grant (A) | — | $0 | EDGAR |
| 2025-04-01 | CDTTW | Grant (A) | +47,612 | $42.4K | EDGAR |
| 2024-12-20 | CDTTW | Grant (A) | — | $0 | EDGAR |
| 2024-11-20 | CDTTW | Grant (A) | +437,976 | $40.2K | EDGAR |
| 2024-05-17 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Grant (A) | +4,095 | $0 | EDGAR |
| 2024-03-28 | PYXS | Grant (A) | +35,219 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.